Orchestra BioMed Holdings, Inc. (OBIO) Insider Trading Activity

NASDAQ$3.09
Market Cap
$118.39M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
196 of 863
Rank in Industry
115 of 492

OBIO Insider Trading Activity

OBIO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$386,226
8
47
Sells
$233,750
9
53

Related Transactions

RTW INVESTMENTS, LP10 percent owner
2
$275,701
0
$0
$275,701
Hochman David PSee Remarks
5
$105,695
0
$0
$105,695
Taylor Andrew LawrenceChief Financial Officer
1
$4,830
0
$0
$4,830
Fain Eric Sdirector
0
$0
4
$38,849
$-38,849
Sherman DarrenSee Remarks
0
$0
5
$194,901
$-194,901

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Insider Activity of Orchestra BioMed Holdings, Inc.

Over the last 12 months, insiders at Orchestra BioMed Holdings, Inc. have bought $386,226 and sold $233,750 worth of Orchestra BioMed Holdings, Inc. stock.

On average, over the past 5 years, insiders at Orchestra BioMed Holdings, Inc. have bought $223,063 and sold $233,750 worth of stock each year.

Highest buying activity among insiders over the last 12 months: RTW INVESTMENTS, LP (10 percent owner) — $275,701. Hochman David P (See Remarks) — $105,695. Taylor Andrew Lawrence (Chief Financial Officer) — $4,830.

The last purchase of 49,900 shares for transaction amount of $149,201 was made by RTW INVESTMENTS, LP (10 percent owner) on 2025‑04‑30.

List of Insider Buy and Sell Transactions, Orchestra BioMed Holdings, Inc.

2025-06-26SaleFain Eric Sdirector
2,683
0.0072%
$3.05
$8,183
-1.34%
2025-04-30PurchaseRTW INVESTMENTS, LP10 percent owner
49,900
0.1311%
$2.99
$149,201
-0.84%
2025-04-29PurchaseRTW INVESTMENTS, LP10 percent owner
50,000
0.1305%
$2.53
$126,500
+16.60%
2024-12-23PurchaseHochman David PSee Remarks
4,000
0.0107%
$4.66
$18,640
-29.10%
2024-12-19PurchaseTaylor Andrew LawrenceChief Financial Officer
1,000
0.0026%
$4.83
$4,830
-30.42%
2024-12-18PurchaseHochman David PSee Remarks
5,000
0.0145%
$4.91
$24,550
-29.83%
2024-09-25PurchaseHochman David PSee Remarks
7,500
0.0166%
$4.75
$35,630
-0.75%
2024-09-24PurchaseHochman David PSee Remarks
2,500
0.0057%
$4.91
$12,275
+1.74%
2024-09-10SaleSherman DarrenSee Remarks
6,904
0.0171%
$5.31
$36,660
-14.96%
2024-09-10SaleFain Eric Sdirector
1,800
0.0045%
$5.34
$9,612
-14.96%
2024-09-09SaleSherman DarrenSee Remarks
6,804
0.0174%
$5.48
$37,286
-14.34%
2024-09-09SaleFain Eric Sdirector
1,800
0.0046%
$5.43
$9,774
-14.34%
2024-09-06SaleSherman DarrenSee Remarks
6,819
0.018%
$5.65
$38,527
-15.86%
2024-09-06SaleFain Eric Sdirector
2,000
0.0053%
$5.64
$11,280
-15.86%
2024-09-05SaleSherman DarrenSee Remarks
6,961
0.019%
$5.85
$40,722
-18.13%
2024-09-04SaleSherman DarrenSee Remarks
6,837
0.0195%
$6.10
$41,706
-22.22%
2024-08-14PurchaseHochman David PSee Remarks
2,500
0.0068%
$5.84
$14,600
-12.82%
2024-06-25PurchaseHochman David PSee Remarks
1,000
0.0032%
$6.95
$6,950
-23.80%
2024-05-30PurchaseLittle William ReedSee Remarks
4,000
0.0131%
$7.00
$28,000
-19.34%
2024-05-17PurchaseHochman David PSee Remarks
3,000
0.0072%
$5.15
$15,450
+4.22%
Total: 21
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
RTW INVESTMENTS, LP10 percent owner
8306063
21.6798%
$25.67M20
Sherman DarrenSee Remarks
765787
1.9988%
$2.37M05
Hochman David PSee Remarks
579498
1.5126%
$1.79M80
<0.0001%
Taylor Andrew LawrenceChief Financial Officer
344960
0.9004%
$1.07M10
Fain Eric Sdirector
50949
0.133%
$157,432.4104
Little William ReedSee Remarks
307859
0.8035%
$951,284.3110
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$5,102,291
146
5.58%
$110.81M
$30,470,407
140
20.39%
$106.76M
$49,091,668
110
13.11%
$104.01M
$48,218,096
42
0.89%
$125.2M
$909,129
37
42.19%
$110.75M
$6,915,275
21
-32.61%
$118.83M
$294,424,120
20
1.33%
$129.54M
$33,027,560
17
-10.02%
$105.49M
$4,701,608
14
-4.34%
$115.43M
$145,194
11
-27.37%
$108.75M
$9,999,920
10
-40.03%
$128.37M
$1,073,250
10
19.46%
$125.66M
$478,647
7
69.41%
$124.34M
$22,090,972
7
-3.49%
$132.51M
$68,692,148
6
-39.10%
$124.17M
$4,745,999
5
-4.91%
$118.18M
$762,555
4
-34.52%
$111.9M
Orchestra BioMed Holdings, Inc.
(OBIO)
$59,900
4
-5.37%
$118.39M
$19,175,155
2
40.00%
$122.87M

OBIO Institutional Investors: Active Positions

Increased Positions23+35.94%240,331+1.23%
Decreased Positions24-37.5%604,257-3.09%
New Positions7New54,119New
Sold Out Positions7Sold Out419,149Sold Out
Total Postitions63-1.56%19M-1.86%

OBIO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Rtw Investments, Lp$22,485.0021.6%8.21M+30%2024-12-31
Perceptive Advisors Llc$12,584.0012.09%4.59M00%2024-12-31
Blackrock, Inc.$5,331.005.12%1.95M-33,174-1.68%2025-03-31
Vanguard Group Inc$3,610.003.47%1.32M+7,767+0.59%2024-12-31
Geode Capital Management, Llc$1,568.001.51%572,441+5,222+0.92%2024-12-31
Price T Rowe Associates Inc /Md/$1,335.001.28%487,170-25,493-4.97%2024-12-31
State Street Corp$1,227.001.18%447,712+18,099+4.21%2024-12-31
Boxer Capital, Llc$653.000.63%238,19300%2024-09-30
Boxer Capital Management, Llc$653.000.63%238,193+238,193New2024-12-31
Northern Trust Corp$649.000.62%236,761+5,725+2.48%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.